Trial Search Results

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Children's Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Other: Laboratory Biomarker Analysis
  • Other: Questionnaire Administration

Eligibility


Inclusion Criteria:

   - ELIGIBILITY CRITERIA - CASES

   - Diagnosis of primary cancer at age 21 or younger, irrespective of current age

   - No prior history of allogeneic (non-autologous) hematopoietic cell transplant

   - Development of one of the following key adverse events at any time following
   initiation of cancer therapy:

      - Cardiac dysfunction; please note: case enrollment has been closed due to
      achievement of target accrual

      - Ischemic stroke (IS)

      - Subsequent malignant neoplasm (SMN)

      - Avascular necrosis (AVN); please note: case enrollment has been closed due to
      achievement of target accrual

   - Submission of a blood specimen (or in certain cases a buccal cell specimen) to the
   Clinical Pharmacokinetics Laboratory at St. Jude Children's Research Hospital as per
   the requirements; please note: if a patient is currently receiving active cancer
   treatment, it is preferable to obtain the blood sample at a time when the patient's
   white blood cell (WBC) is > 2,000

   - Written informed consent from the patient and/or the patient's legally authorized
   guardian

   - In active follow up by a COG institution; active follow up will be defined as date of
   last visit or contact by a COG institution within the past 24 months; any type of
   contact, including contact specifically for participation in ALTE03N1, qualifies as
   active follow-up; please note: treatment on a COG (or legacy group) therapeutic
   protocol for the primary cancer is NOT required

   - ELIGIBILITY CRITERIA - CONTROLS

   - CONTROL: Diagnosis of primary cancer at age 21 or younger, irrespective of current age

   - CONTROLS: No prior history of allogeneic (non-autologous) hematopoietic cell
   transplant

   - CONTROLS: No clinical evidence of any of the following key adverse events:

      - Cardiac dysfunction (CD); please note: if a patient is currently receiving active
      cancer treatment, it is preferable to obtain the blood sample at a time when the
      patient's WBC is > 2,000

      - Myocardial infarction (MI)

      - Ischemic stroke (IS)

      - Avascular necrosis (AVN)

      - Subsequent malignant neoplasm (SMN)

   - CONTROLS: Submission of a blood specimen (or in certain cases a buccal cell specimen)
   to the Clinical Pharmacokinetics Laboratory at St. Jude Children's Research Hospital
   as per the requirements

   - CONTROLS: Written informed consent from the patient and/or the patient's legally
   authorized guardian

   - CONTROLS: In active follow up by a COG institution; active follow up will be defined
   as date of last visit or contact by a COG institution within the past 24 months; any
   type of contact, including contact specifically for participation in ALTE03N1,
   qualifies as active follow-up; please note: treatment on a COG (or legacy group)
   therapeutic protocol for the primary cancer is NOT required

Ages Eligible for Study

N/A - 21 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting